Cipher Pharmaceuticals Inc.

TSX:CPH.TO

Drug Manufacturers - Specialty & Generic

Healthcare
$13.05 +0.94%

+$0.15 today

Market cap
$331.67M
Beta
0.48
P/E (TTM)
9.3
EPS (TTM)
$1.22
52W Low $11.98High $20.56

Volume 0.04M

Average 0.03M

CPH.TO Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Cipher Pharmaceuticals Inc.TSX: CPH.TO

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization dips below year-ago levels

Q1 FY2026 depreciation & amortization of $1.78M fell 2.4% year over year, behind the +29.5% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 1.6% from the prior quarter. Over 3 fiscal years it compounded at +94.1% a year.

Context

  • Depreciation & amortization amounted to 14.1% of revenue in FY2025, up 2.0 pp from a year earlier.
  • Depreciation & amortization increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -2.4% toward the trailing-twelve-month pace of +29.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.78M-1.6% QoQ
Last fiscal yearDec 2025
$7.23M+80.0% YoY
LTMMar 2026
$7.19M+29.5% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-2.4%——
1 year+80.0%——
3-year CAGR+94.1%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
7.23M USD
Year-over-year change
+80.0%
4-year CAGR
+79.2%

Depreciation & Amortization vs competitors

How CPH.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +29.5% is the 2nd highest of 8, against a peer median of +2.0%.
  • Depreciation & amortization amounts to 14.1% of revenue for CPH.TO, versus a peer median of 7.2%.
CPH.TO Competitors
Depreciation & Amortization for CPH.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GUD.TOKnight Therapeutics Inc.LTM Mar 2026CA$61.18M CAD+17.4%-3.3%12.0%
WEED.TOCanopy Growth CorporationLTM Mar 2026CA$40.12M CAD-6.9%-23.0%12.9%
OGI.TOOrganiGram Holdings Inc.LTM Mar 2026CA$19.76M CAD+37.8%—7.2%
TSND.TOTerrAscend Corp.LTM Mar 2026$16.18M USD-28.9%-10.7%6.2%
ACB.TOAurora Cannabis Inc.LTM Mar 2026CA$13.39M CAD-40.6%-31.2%4.2%
CPH.TOCipher Pharmaceuticals Inc.LTM Mar 2026$7.19M USD+29.5%+94.1%14.1%
EDT.TOSpectral Medical Inc.LTM Mar 2026CA$253K CAD+2.0%-2.8%9.2%
FRX.TOFennec Pharmaceuticals Inc.LTM Mar 2026$128K USD+24.3%-11.6%0.3%
Peer median (excluding CPH.TO) —+2.0%-11.2%7.2%

Competitors are the stored peer set for CPH.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue21.94M20.68M21.16M33.36M51.33M
Cost of Revenue3.68M3.99M4.07M9.26M17.56M
Gross Profit18.26M16.68M17.09M24.1M33.77M
Gross Margin83.2%80.7%80.8%72.2%65.8%
Research & Development88K98K139K021.37K
Selling, General & Admin5.11M4.4M5.43M12.24M16.3M
Operating Expenses6.45M5.63M5.56M16.26M16.97M
Depreciation & Amortization701K989K1.23M4.02M7.23M
EBITDA13.66M12.04M11.53M11.87M24.1M
EBITDA Margin62.2%58.2%54.5%35.6%46.9%
Operating Income11.82M12.04M11.53M7.85M16.8M
Operating Margin53.9%58.2%54.5%23.5%32.7%
Interest Income12K464K1.87M330K0
Interest Expense92K0001.19M
Other Income / Expenses(2M)(560K)1.15M(4.89M)661.38K
Income Before Tax11.06M11.48M12.68M2.96M17.46M
Pre-Tax Margin50.4%55.5%59.9%8.9%34.0%
Income Tax Expense3.3M(15.16M)(7.7M)(8.59M)(10.34M)
Net Income7.76M26.64M20.38M11.55M27.81M
Net Margin35.4%128.8%96.3%34.6%54.2%
EPS (Basic)0.291.060.800.471.09
EPS (Diluted)0.291.040.800.471.07
Weighted Avg Shares26.6M25.13M25.48M24.72M25.48M
Weighted Avg Shares (Diluted)26.83M25.59M25.42M24.57M25.99M

Cipher Pharmaceuticals Inc.

TSX:CPH.TO

Intrinsic Alpha fair value

Locked

Current Price

$13.05

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.